BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Interest Income

Income earned on cash, deposits, and investments held by the company.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Interest Income · Q3 FY2026 · quarter ended Sep 2026

Interest income growth accelerates

Q3 FY2026 interest income of $4.63B rose 25832.6% year over year, ahead of the +6281.3% change in trailing-twelve-month interest income. Sequentially, it rose 44079.4% from the prior quarter. Over 3 fiscal years it compounded at +60.7% a year.

Context

  • Interest income amounted to 2.3% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25832.6% holds above the trailing-twelve-month pace of +6281.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$4.63B+44079.4% QoQ
Last fiscal yearDec 2025
$74.9M+0.0% YoY
LTMSep 2026
$4.68B+6281.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25832.6%——
1 year+0.0%——
3-year CAGR+60.7%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
74.9M USD
Year-over-year change
+0.0%
4-year CAGR
+63.5%

Interest Income vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6281.3% is the highest of 10, against a peer median of -7.8%.
  • Interest income amounts to 0.5% of revenue for BMRN, versus a peer median of 3.5%.
BMRN Competitors
Interest Income for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$4.68B USD+6281.3%+60.7%0.5%
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 2026$475.7M USD-4.3%+50.3%3.7%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$110.05M USD-7.8%+65.0%2.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$89.99M USD-11.7%+56.9%9.4%
ASNDAscendis Pharma A/SLTM Sep 2026€56.37M EUR+172.4%+25.6%4.7%
INSMInsmed IncorporatedLTM Jun 2026$45.57M USD-25.8%+76.2%4.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$24.17M USD-30.0%+31.2%3.6%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$23.48M USD+36.0%+38.1%3.3%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$12.24M USD-12.1%+26.6%1.9%
PHARPharming Group N.V.LTM Mar 2026$4.38M USD+27.1%+211.0%1.2%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding BMRN) —-7.8%+50.3%3.5%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.85B2.1B2.42B2.85B3.22B
Cost of Revenue470.52M503.02M532.06M580.24M736.83M
Gross Profit1.38B1.59B1.89B2.27B2.48B
Gross Margin74.5%76.0%78.0%79.7%77.1%
Research & Development628.79M649.61M746.77M747.18M921.93M
Selling, General & Admin759.4M823.2M892.4M1.01B1.28B
Operating Expenses1.46B1.43B1.7B1.79B1.95B
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
EBITDA47.43M265.36M306.77M650.53M572.94M
EBITDA Margin2.6%12.7%12.7%22.8%17.8%
Operating Income(82.34M)160.97M185.77M484.21M533.48M
Operating Margin-4.5%7.7%7.7%17.0%16.6%
Interest Income10.48M18.03M58.34M74.88M74.9M
Interest Expense15.34M15.97M17.34M12.67M10.9M
Other Income / Expenses6.99M(11.4M)2.79M57.55M(51M)
Income Before Tax(75.35M)149.58M188.56M541.76M482.48M
Pre-Tax Margin-4.1%7.1%7.8%19.0%15.0%
Income Tax Expense(11.27M)8.02M20.92M114.9M133.58M
Net Income(64.08M)141.56M167.65M426.86M348.9M
Net Margin-3.5%6.8%6.9%15.0%10.8%
EPS (Basic)(0.35)0.760.892.251.82
EPS (Diluted)(0.35)0.750.882.211.80
Weighted Avg Shares182.85M185.27M187.83M190.03M191.79M
Weighted Avg Shares (Diluted)182.85M188.96M191.6M196.71M197.39M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.